Welcome to our dedicated page for Burning Rock Biotech news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech stock.
Burning Rock Biotech Limited (BNR) reports developments in next-generation sequencing technology for precision oncology. Its news commonly covers financial results, Form 20-F annual reporting, annual general meeting actions, ADS-related ownership announcements, and clinical or regulatory updates for NGS assays used in therapy selection, MRD assessment, companion diagnostics and cancer early detection.
Company updates reference products and technologies such as OncoScreen, CanCatch and ELSA-seq, including study publications, patent grants and companion-diagnostic approvals connected to precision oncology testing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR) announced plans to release its unaudited financial results for Q1 2023 on May 30, 2023, before U.S. market opens. Management will hold a conference call at 8:00 a.m. ET on the same day. The company anticipates moderate revenue growth year-over-year, driven by a strong rebound in March, reversing previous declines in January-February. March 2023 total test volumes increased by approximately 29% year-over-year, attributed mainly to growth in the in-hospital channel. Investors can register for the call and access a live webcast on the company’s investor relations website.
Burning Rock Biotech Limited (NASDAQ: BNR), focused on next-generation sequencing technology for precision oncology, filed its Annual Report on Form 20-F for the fiscal year ending December 31, 2022, with the U.S. SEC on April 21, 2023. The report is accessible on both the SEC website and the company's own site.
Burning Rock's business segments include NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has advanced to the clinical validation phase. The company's mission remains centered on enhancing cancer care through scientific innovation.